Medically reviewed by Drugs.com.
By Ernie Mundell HealthDay Reporter
The U.S. Food and Drug Administration on Friday has for the first time approved the use of a respiratory syncytial virus (RSV) vaccine for people in their 50s who are at increased risk for the illness.
- Drugmaker GSK’s Arexvy vaccine, as well as vaccines from Pfizer and Moderna, are already
approved for use in adults 60 and older, since age brings higher risk from RSV disease. - Arexvy is the first to get the nod for people ages 50 to 59 with certain health risk factors.
